The below responses are for the time period 01/01/2024 to 30/06/2024 inclusive.
Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?
15
Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?
13
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
· R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
11
· R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
NIL
· Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
<5
· Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
15
· R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
NIL – This treatment is not offered at ELHT.
· R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
NIL – This treatment is not offered at ELHT.
· Axicabtagene ciloleucel
NIL – This treatment is not offered at ELHT.
· Tisagenlecleucel
NIL – This treatment is not offered at ELHT.
· Epcoritamab
NIL
· Loncastuximab tesirine
NIL
· Glofitamab
NIL
· Any other SACT
15
· Stem cell transplant or bone marrow transplant (autologous or allogeneic)
NIL – This treatment is not offered at ELHT.
Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
· Axicabtagene ciloleucel (Yescarta)
NIL
· Tisagenlecleucel
NIL
· Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
<5
· Stem cell transplant or bone marrow transplant (autologous or allogeneic)
This treatment is not offered at ELHT.
· Any other treatments
44
Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
· CAR-T Therapy (E.g. Axicabtagene ciloleucel) - NIL
Stem cell transplant or bone marrow transplant (autologous or allogeneic) - This treatment is not offered at ELHT.
· Any other treatment - NIL
Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?
No, the Trust do not participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL).
